Tower Research Capital (TRC)’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-41
| Closed | -$1.63K | – | 5270 |
|
|
2026
Q1 | $1.63K | Sell |
41
-1,090
| -96% | -$27.9K | ﹤0.01% | 4627 |
|
|
2025
Q4 | $28.3K | Sell |
1,131
-2,780
| -71% | -$70.4K | ﹤0.01% | 2841 |
|
|
2025
Q3 | $94.8K | Buy |
3,911
+3,432
| +716% | +$61K | ﹤0.01% | 2030 |
|
|
2025
Q2 | $6.29K | Sell |
479
-440
| -48% | -$5.58K | ﹤0.01% | 4115 |
|
|
2025
Q1 | $13.2K | Sell |
919
-942
| -51% | -$15.4K | ﹤0.01% | 3390 |
|
|
2024
Q4 | $31.2K | Sell |
1,861
-428
| -19% | -$7.09K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $36.6K | Buy |
2,289
+991
| +76% | +$12.1K | ﹤0.01% | 2898 |
|
|
2024
Q2 | $11.7K | Buy |
1,298
+288
| +29% | +$2.73K | ﹤0.01% | 4067 |
|
|
2024
Q1 | $11.4K | Sell |
1,010
-1,293
| -56% | -$12.2K | ﹤0.01% | 3570 |
|
|
2023
Q4 | $18.3K | Sell |
2,303
-763
| -25% | -$5.12K | ﹤0.01% | 3705 |
|
|
2023
Q3 | $19.8K | Sell |
3,066
-1,206
| -28% | -$8.25K | ﹤0.01% | 3381 |
|
|
2023
Q2 | $26.4K | Sell |
4,272
-4,302
| -50% | -$20.4K | ﹤0.01% | 3139 |
|
|
2023
Q1 | $33K | Sell |
8,574
-7,597
| -47% | -$27.8K | ﹤0.01% | 2886 |
|
|
2022
Q4 | $51K | Buy |
16,171
+10,894
| +206% | +$40.4K | ﹤0.01% | 2327 |
|
|
2022
Q3 | $21K | Buy |
5,277
+3,800
| +257% | +$17.4K | ﹤0.01% | 3888 |
|
|
2022
Q2 | $7K | Buy |
1,477
+232
| +19% | +$1.48K | ﹤0.01% | 4774 |
|
|
2022
Q1 | $11K | Buy |
1,245
+315
| +34% | +$2.87K | ﹤0.01% | 4155 |
|
|
2021
Q4 | $10K | Buy |
930
+811
| +682% | +$10.9K | ﹤0.01% | 4540 |
|
|
2021
Q3 | $2K | Sell |
119
-958
| -89% | -$19.8K | ﹤0.01% | 5242 |
|
|
2021
Q2 | $24K | Buy |
+1,077
| New | +$25.3K | ﹤0.01% | 3717 |
|
Tower Research Capital (TRC)'s CNTA Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 41 shares — an estimated $1.63K sold.
Tower Research Capital (TRC) first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $94.8K in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 41 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.63K.
- Tower Research Capital (TRC) first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Tower Research Capital (TRC)'s Centessa Pharmaceuticals position peaked at $94.8K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.